Security
XBIO · Xenetic Biosciences, Inc.
XBIONASDAQCommon stockCurrentCIK 1534525Updated Sep 26, 2026
Name history
General Sales & Leasing, Inc. · through Jan 10, 2014GENERAL AIRCRAFT INC. · through Feb 12, 2013
XBIO price & chart
Loading TradingView…
NASDAQ:XBIO on TradingView ↗About the company
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
SCHEDULE 13G - filed by MJL Manager LLC regarding Xenetic Biosciences, Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
10-K/A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 8,363,847Source | 6,901,443Source | 10,605,226Source | 14,720,290Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 0Source |
| Current assets: | ||||
| Assets, CurrentUSD | 8,049,926Source | 6,587,522Source | 9,586,874Source | 13,653,359Source |
| Prepaid Expense and Other Assets, CurrentUSD | 166,294Source | 421,954Source | 603,828Source | 556,094Source |
| Other Assets, NoncurrentUSD | 313,921Source | 313,921Source | 1,018,352Source | 1,066,931Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 968,025Source | 894,263Source | 809,585Source | 1,073,156Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,294Source | 1,545Source | 1,544Source | 15,192Source |
| Additional Paid in CapitalUSD | 212,294,851Source | 208,225,748Source | 208,053,935Source | 207,756,232Source |
| Retained Earnings (Accumulated Deficit)USD | -199,875,331Source | -197,194,471Source | -193,234,196Source | -189,099,618Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 253,734Source | 253,734Source | 253,734Source | 253,734Source |
| Stockholders' Equity Attributable to ParentUSD | 7,395,822Source | 6,007,180Source | 9,795,641Source | 13,647,134Source |
| Liabilities and EquityUSD | 8,363,847Source | 6,901,443Source | 10,605,226Source | 14,720,290Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 968,025Source | 894,263Source | 809,585Source | 1,073,156Source |
| Accounts Payable, CurrentUSD | 258,109Source | 283,615Source | 240,832Source | 287,360Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 709,916Source | 610,648Source | 568,753Source | 785,796Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 64,787Source | 171,814Source | 283,085Source | 511,480Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -2,286,651Source | -2,817,478Source | -4,114,219Source | -4,646,765Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | 0Source | -500,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,004,715Source | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,883,632Source | 6,165,568Source | 8,983,046Source | 13,097,265Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 100,000Source | 200,000Source | 300,000Source | 500,000Source |
| General and Administrative ExpenseUSD | 2,745,509Source | 3,416,380Source | 3,560,936Source | 3,653,999Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -2,680,860Source | -3,960,275Source | -4,134,578Source | -6,552,353Source |
| Nonoperating Income (Expense)USD | 153,722Source | 244,153Source | 381,137Source | 165,555Source |
| Operating ExpensesUSD | 5,810,993Source | 6,704,712Source | 7,055,701Source | 8,424,833Source |
| Other Nonoperating Income (Expense)USD | 5,725Source | -5,708Source | 25,380Source | -1,597Source |
| Proceeds from Issuance of Common StockUSD | 4,004,715Source | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,976,411Source | 2,500,284Source | 2,539,986Source | 1,706,925Source |
| Operating Income (Loss)USD | -2,834,582Source | -4,204,428Source | -4,515,715Source | -6,717,908Source |
| Other Nonoperating Income (Expense)USD | 5,725Source | -5,708Source | 25,380Source | -1,597Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -2,680,860Source | -3,960,275Source | -4,134,578Source | -6,552,353Source |
| Earnings Per Share, BasicUSD per share | -1.58Source | -2.57Source | -2.71Source | -0.46Source |
| Earnings Per Share, DilutedUSD per share | -1.58Source | -2.57Source | -2.71Source | -0.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,701,571Source | 1,541,339Source | 1,528,210Source | 14,224,430Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,701,571Source | 1,541,339Source | 1,528,210Source | 14,224,430Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 2,745,509Source | 3,416,380Source | 3,560,936Source | 3,653,999Source |
| Interest Income (Expense), NetUSD | 147,997Source | 249,861Source | 355,757Source | 167,152Source |
| Nonoperating Income (Expense)USD | 153,722Source | 244,153Source | 381,137Source | 165,555Source |
| Operating ExpensesUSD | 5,810,993Source | 6,704,712Source | 7,055,701Source | 8,424,833Source |
| Other Cost and Expense, OperatingUSD | 3,018,568Source | 1,898,121Source | — | — |
| Other General ExpenseUSD | — | 45,000Source | — | — |
| Research and Development ExpenseUSD | 3,065,484Source | 3,288,332Source | 3,494,765Source | 4,770,834Source |